TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pulpotomy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of PPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains of RAL-V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of images
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence level of diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality during hospital stay
Endpoint domain: Mortality/survival
Primary endpoint: Mortality within 100 days of discharge
Endpoint domain: Mortality/survival
Primary endpoint: hSBA titers >5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SBP response to CSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Persistence of unexplained complaints after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (QoL) on the physical domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life (QoL) on the mental domain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median survival from initiation of topotecan therapy
Endpoint domain: Mortality/survival
Primary endpoint: Distance corrected near acuity of J6 (20/40) or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected distance acuity of 20/20 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life postoperatively (measured with the VF-7)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Testosterone (T) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Perception ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain interference with daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of VAAI
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of VAAI and VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Prediction of Ceprop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure increase with eyelid closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: incidence of arrests
Endpoint domain: Adverse events/effects
Primary endpoint: 3-methylhistidine to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of women without metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of hypomelanotic macules (in δ‐L values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Oral mucosa adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty with instrumental activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difficulty with activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinically significant short-term weight loss (≥5%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer stressors in their role as parent
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: increased social support at work
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: less anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: independence in instrumental activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean 24-h energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intention to participate in genetic research
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: ΔeGFR progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Facial reactivity during Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) reactivity during Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infectious events
Endpoint domain: Adverse events/effects
Primary endpoint: Days in bed
Endpoint domain: Resource use
Primary endpoint: Fractional cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of documented problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRV decline related to PM2.5 exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sedation scores
Endpoint domain: Adverse events/effects
Primary endpoint: Non-attendance at preventive health checks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: myopia progression at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological falls risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo implantation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of patients achieving significant improvement in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of depression remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: increased mental health care interactions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increased psychosocial distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of severe-range hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean total procedure times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS scores for dentist's assessment of difficulty
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean VAS scores for patients' assessment of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rifampin peak concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-24 hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-normalized clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IEF/week reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IEF responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence quality of life questionnaire (I-QOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean papule counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Favorable attitude toward living liver donation (LLD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum rise in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late postoperative nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Late postoperative vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in severe snoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of malocclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to return to full sports activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median effective dose for loss of consciousness (LOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until discharge readiness from the operating room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery room discharge times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lowered respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increased end-expiratory lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IOP readings comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dressing change frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily material costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of correct guesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of sites with probing depths >=3.5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Resolution of chronic idiopathic urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical failure
Endpoint domain: Adverse events/effects
Primary endpoint: graft rupture
Endpoint domain: Adverse events/effects
Primary endpoint: Leg circumference change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in paralytic ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PACRR scale reliability and validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of angiographic MVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ST-segment resolution greater than or equal to 70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hs-CRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prealbumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Laryngeal symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal signs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PMNE levels in peripheral venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MPO levels in peripheral venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cancer-related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Additional analgesic requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of physiologic dependence on BUP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias in CO measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic relief for severe and intractable pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin irritation as an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Intention to donate blood
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compressive fracture strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Vascular Resistance (CVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot-flash frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot-flash severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Arterial Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurocognitive dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: maximum increase in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average change in 1‐sec forced expiratory volume at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: relative bioavailability for DPIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recuperative effect after sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: HAMA psychic anxiety sub-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful treatment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain reaction scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain perception scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder-tip pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting concentrations of intact GLP‐1 and GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MCRs of intact GLP‐1 and GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T1/2 of intact and metabolite forms of GLP‐1 and GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BPH Impact Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OUES improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in MCA after antigen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of fatal outcome
Endpoint domain: Mortality/survival
Primary endpoint: Aortic valve peak gradient reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ejection time increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent Phrenic Nerve Palsy (PNP)
Endpoint domain: Adverse events/effects
Primary endpoint: Transient Phrenic Nerve Palsy (PNP)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to restitution of Phrenic Nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Histological funisitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spermatic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: spermatic motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pregnant rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: reduced disability at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pulmonary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity for clinically significant PTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mobility-related self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: stair climb performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of morbidity and mortality associated with malaria
Endpoint domain: Mortality/survival
Primary endpoint: Rate of undesirable outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of follow-up within 21 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of completed outpatient workups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the concentration-time curve (AUC infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance (CLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Child weight and weight-related outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of positive cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Airway dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Propofol dosage for induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T helper lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative pain scores (0-48 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients experiencing ≥7/10 pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total opiate use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box and Block test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual Function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl‐Meyer scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood culture contamination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PSA recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average evaporative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of withdrawal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of sexual performance
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Histamine-induced wheal and flare suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weekly symptom and medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: specific nasal threshold to Dermatophagoides antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: good BMI outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-year changes in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in high-density-lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvements in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: radiological progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SIM confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge index scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status